Daily Sync-Biotic

Categories: ,


Daily Sync-Biotic is a foundational probiotic supplement featuring a 50:50 blend of patented Lactobacillus acidophilus NCFM® and Bifidobacterium lactis Bi-07®—two of the most thoroughly studied probiotic strains.


How Daily Sync-Biotic Works

For daily gut and immune support, Daily Sync-Biotic provides 15 billion colony-forming units (CFU) per serving of these synergistic probiotic strains (in a 50:50 ratio), coming in both 60 and 120 serving size options. Read on to learn more about how the probiotics in Daily Sync-Biotic work and their evidence-based benefits.

Lactobacillus acidophilus NCFM®

L. acidophilus NCFM®, which stands for the research laboratory it was first discovered at (“North Carolina Food Microbiology” lab), is a patented beneficial lactic acid bacteria strain often used to support lactose intolerance by promoting the digestion of simple sugars and other tough-to-digest nutrients. 2

Daily Sync-Biotic Supplementation

There are actually over 50 human clinical trials on these specific strains, confirming their position as two of the leading probiotic strains in the world. The findings of these studies continue to demonstrate the synergy of Lactobacillus acidophilus NCFM® and Bifidobacterium lactis Bi-07® for supporting healthy gut flora balance, immune function, and proper digestion of vital nutrients. 1

Daily Sync-Biotic contains two of the most embraced probiotic strains for balancing the gut microbiome and supporting healthy immune response. A bevy of clinical research suggests that Lactobacillus acidophilus NCFM® and Bifidobacterium lactis Bi-07® may:

  • Support healthy gut flora balance
  • Support healthy immune function
  • Support nutrient absorption
  • Support digestive function


1. Fijan, S. (2014). Microorganisms with claimed probiotic properties: an overview of recent literature. International journal of environmental research and public health, 11(5), 4745-4767.

2. Malcolm W. Hickey, Alan J. Hillier, G. Richard Jago (1986). Transport and Metabolism of Lactose, Glucose, and Galactose in Homofermentative Lactobacilli. Appl Environ Microbiol.; 51(4): 825–831.

3. Rousseaux C. et al., (2007), ‘Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors’. Nature Medicine, 13(1):35-7.

4. Ringel-Kulka T., et al., (2011). ‘Probiotic Bacteria Lactobacillus acidophilus NCFM and Bifido bacterium lactis Bi-07 Versus Placebo for the Symptoms of Bloating in Patients with Functional Bowel Disorders. A Double-blind Study’. Journal of Clinical Gastroenterology, 45: 518- 525.

5. Sanders M. E, and Klaenhammer, T. R., (2001). ‘Invited Review: The Scientific Basis of Lactobacillus acidophilus NCFM Functionality as a Probiotic’. Journal of Dairy Science Vol. 84(2):319-331.

6. Ringel-Kulka T., et al., (2014). ‘Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain – a randomised clinical study’. Aliment Pharmacological Therapy., 40(2):200-7. doi: 10.1111/apt.12800

7. Rossi, M., Amaretti, A., & Raimondi, S. (2011). Folate production by probiotic bacteria. Nutrients, 3(1), 118-134.

8. Hyronimus, B., Le Marrec, C., Sassi, A. H., & Deschamps, A. (2000). Acid and bile tolerance of spore-forming lactic acid bacteria. International journal of food microbiology, 61(2), 193-197.

9. Karina Pokusaeva, Gerald F. Fitzgerald,Douwe van Sinderen (2011). Carbohydrate metabolism in Bifidobacteria. Genes Nutr.; 6(3): 285–306.

10. Cox et al., (2014). ‘Effects of probiotic supplementation over 5 months on routine haematology and clinical chemistry measures in healthy active adults’, Eur J Clin Nutr.,
68(11):1255-7. doi: 10.1038/ejcn.2014.137. Epub 2014 Jul 23.

11. Maneerat S. et al., (2013). ‘Consumption of Bifidobacterium lactis Bi-07 by healthy elderly adults enhances phagocytic activity of monocytes and granulocytes’ J Nutr Sci.., 2(2):e44.

12. Engelbrektson, AL, et al (2009) ‘A randomized, double blind, controlled trial of probiotics to minimize the disruption of fecal microbiota in healthy subjects undergoing antibiotic therapy’. Journal of Medical Microbiology, 58:663-670